Note: Ingredients listed on restricted chemical lists
EC/CAS
237-159-2/13674-87-8
Name of the chemical
Tris(1,3-dichloro-isopropyl)phosphate (TDCP)
Concentration
<= 100 %
General Information
Version
7.3
Revision date
2023-06-02
Product name
TDCPP
CAS No.
13674-87-8
REACH No
is
Emergency telephone
+33 (0)9 75 18 14 07, +33 (0)1 45 42 59 59
Icons in SDS
Company Information
company name
Merck Life Science S.A.S
e-mail address of the competent person responsible for the Safety Data Sheet
servicetechnique@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H351, H410
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Warning Warning
Hazard statements
H351 Suspected of causing cancer. H410 Very toxic to aquatic life with long lasting effects. H351 Suspected of causing cancer.
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage. P405 Store locked up. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P405 Store locked up.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Carcinogenicity (Category 2), H351 Long-term (chronic) aquatic hazard (Category 1), H410 For the full text of the H-Statements mentioned in this Section, see Section 16.
